Celldex Therapeutics Inc (CLDX)
37.92
-0.56
(-1.46%)
USD |
NASDAQ |
Apr 19, 16:00
37.92
0.00 (0.00%)
After-Hours: 17:29
Celldex Therapeutics Research and Development Expense (Quarterly): 30.43M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 30.43M |
| September 30, 2023 | 34.54M |
| June 30, 2023 | 26.25M |
| March 31, 2023 | 26.80M |
| December 31, 2022 | 22.90M |
| September 30, 2022 | 21.57M |
| June 30, 2022 | 20.73M |
| March 31, 2022 | 17.06M |
| December 31, 2021 | 14.68M |
| September 30, 2021 | 13.56M |
| June 30, 2021 | 12.36M |
| March 31, 2021 | 12.72M |
| December 31, 2020 | 10.42M |
| September 30, 2020 | 10.71M |
| June 30, 2020 | 9.705M |
| March 31, 2020 | 11.70M |
| December 31, 2019 | 10.34M |
| September 30, 2019 | 11.10M |
| June 30, 2019 | 10.08M |
| March 31, 2019 | 11.15M |
| December 31, 2018 | 11.21M |
| September 30, 2018 | 11.92M |
| June 30, 2018 | 21.45M |
| March 31, 2018 | 21.88M |
| December 31, 2017 | 23.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 21.92M |
| June 30, 2017 | 25.00M |
| March 31, 2017 | 25.79M |
| December 31, 2016 | 24.56M |
| September 30, 2016 | 25.01M |
| June 30, 2016 | 25.71M |
| March 31, 2016 | 27.45M |
| December 31, 2015 | 23.90M |
| September 30, 2015 | 24.66M |
| June 30, 2015 | 26.49M |
| March 31, 2015 | 25.12M |
| December 31, 2014 | 27.03M |
| September 30, 2014 | 26.18M |
| June 30, 2014 | 24.10M |
| March 31, 2014 | 27.07M |
| December 31, 2013 | 17.80M |
| September 30, 2013 | 20.42M |
| June 30, 2013 | 15.09M |
| March 31, 2013 | 14.09M |
| December 31, 2012 | 13.75M |
| September 30, 2012 | 11.77M |
| June 30, 2012 | 11.11M |
| March 31, 2012 | 10.77M |
| December 31, 2011 | 9.824M |
| September 30, 2011 | 8.594M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.705M
Minimum
Jun 2020
34.54M
Maximum
Sep 2023
17.24M
Average
13.56M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| ThermoGenesis Holdings Inc | 0.329M |
| Perspective Therapeutics Inc | 6.08M |
| Electromed Inc | 0.107M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |